Clinical trials located in

Brescia

Brescia city is located in Italy. Currently, 20 clinical trials are being conducted in this city.

Brescia, located in Lombardy, Italy, boasts a rich history dating back over 3,200 years. Known as the “Lioness of Italy” for its tenacious resistance during the Ten Days of Brescia against Austrian rule, the city is a treasure trove of ancient, medieval, and Renaissance landmarks. Its Roman ruins, including the Capitolium and the Roman theatre, are among the most significant in Northern Italy. Brescia is also home to the UNESCO World Heritage site of the Longobards, showcasing the city’s pivotal role during the Lombard period. The Mille Miglia, an iconic vintage car race, starts and ends in Brescia, highlighting its cultural and historical significance.

  • CT-EU-00119838

    Study on the effectiveness and safety of M281 in adults with warm Autoimmune Hemolytic Anemia

    The study focuses on Warm Autoimmune Hemolytic Anemia (wAIHA), a condition where the immune system mistakenly destroys red blood cells. This leads to symptoms like fatigue, weakness, and jaundice (yellowing of the skin or eyes). The trial examines the effects of a therapy named M281 (Nipocalimab). The purpose of the study is to evaluate the efficacy and safety of M281. Patients participating in the study will receive either M281 or a placebo. It aims to compare improvements in health and monitor any side effects.

    The study structure is as follows:

    Double-blind period: This lasts for 24 weeks, where participants will be randomly assigned to one of three groups. One group will receive M281 every 4 weeks, alternating with a placebo every 4 weeks. Another group will receive M281 every 2 weeks, and the third group will receive a placebo every 2 weeks.

    Open-label extension period: This phase extends for 144 weeks, where all participants will receive M281, either every 2 weeks or every 4 weeks.

    Participants will be monitored for 8 weeks after the last dose to check for any ongoing effects of the treatment. The study aims to provide comprehensive information about the effectiveness and safety of M281 in treating wAIHA.

    • M281
    • placebo
  • Testing Gantenerumab and Drug Combinations for Early Onset Alzheimer’s Disease in Families with Genetic Mutations

    This study focuses on Alzheimer’s disease, particularly an early onset type caused by a genetic mutation inherited dominantly. Various therapies will be tested, including Gantenerumab, Solanezumab, Etalanetug, and Lecanemab. The purpose is to assess the safety, tolerability, and effectiveness of these treatments in slowing the progression or improving markers of the disease.

    The study targets individuals who either have a mutation causing Alzheimer’s disease or are at risk of having such a mutation. Participants can be without symptoms or have mild signs of dementia. Both actual medications and placebo will be used to compare the effectiveness of the treatments.

    Gantenerumab is administered subcutaneously (under the skin) every four weeks, while Solanezumab is given through intravenous (IV) infusion every four weeks. Etalanetug and Lecanemab are also administered intravenously. The study design includes different stages, where the participants and research staff may or may not know which specific treatment the participant is receiving, depending on the mutation and the drug being tested.

    This adaptive study aims to find effective treatments by testing multiple therapies. The study will analyze biomarkers (biological markers) from imaging and body fluids and assess clinical and cognitive outcomes to see if the treatments are working on a biological and clinical level. After the main treatment phase, there is an option for participants to receive the active drug in an open-label extension phase.

    • Etalanetug
    • Gantenerumab
    • Solanezumab
    • Lecanemab
  • Baricitinib study in children with juvenile idiopathic arthritis

    This clinical trial is designed to test whether Baricitinib is safe and effective in the treatment of systemic juvenile idiopathic arthritis in children aged 1 to 18 years. Participants will be assigned to one of two groups. In the first group, some participants will receive Baricitinib and others Tocilizumab as the reference drug. In the second group, all participants will receive Baricitinib.

    The primary objective of the study is to evaluate the percentage of participants who experience at least a 30% improvement in disease symptoms after 12 weeks of treatment according to the modified American College of Rheumatology Pediatric Response Criteria (PediACR30). Baricitinib is administered orally and Tocilizumab is administered by subcutaneous injection.

    • Tocilizumab
    • baricitinib
  • Study of ustekinumab and guselkumab in young patients with juvenile psoriatic arthritis

    This here clinical trial is aimin’ to study two different medicines, ustekinumab and guselkumab, for treatin’ a condition called juvenile psoriatic arthritis. This is a type of arthritis that affects young’uns and causes joint pain, swellin’, and stiffness.

    The study will have two groups, one group takin’ ustekinumab and the other takin’ guselkumab. These medicines work by targetin’ certain proteins in the body that cause inflammation, which is the root cause of the arthritis symptoms.

    The main goal of the study is to see how well these medicines work in reducin’ the symptoms of juvenile psoriatic arthritis, like joint pain and swellin’. The study will also look at how the body handles these medicines and if they cause any side effects.

    The study will last for about a year and a half, with regular check-ups and assessments to monitor the participants’ progress.

    • Ustekinumab
    • Guselkumab
  • Study on combining two drugs – Fianlimab and Cemiplimab in patients with previously untreated melanoma

    This study examines two drugs, fianlimab and cemiplimab, given together for the treatment of melanoma. The main goal is to see how effective this drug combination is in treating melanoma compared with pembrolizumab, which is already approved for the treatment of melanoma in adults. The study will also look at whether there are any differences in the effects of these experimental drugs in adolescents and adults.

    Scientists also want to learn about other key issues: what side effects may occur from taking these experimental drugs, how much of the drugs enter the bloodstream over time, and whether the body produces antibodies to the drugs that could make them less effective or cause side effects. They will also check whether taking medications improves patients’ quality of life. Fianlimab and cemiplimab will be administered by intravenous infusion, and pembrolizumab will be administered by intravenous infusion.

    • placebo
    • Fianlimab
    • Cemiplimab
    • Pembrolizumab
  • Study on Ravulizumab’s effect on Immunoglobulin A Nephropathy

    The study is looking into the effectiveness of a medication called ravulizumab for adults who have a kidney condition known as Immunoglobulin A Nephropathy (IgAN). This condition can lead to kidney damage over time, and the study aims to find out if ravulizumab can help reduce the amount of protein lost in urine—a common problem in IgAN—and slow down the decrease in kidney function.

    In this study, about 450 participants who are at a high risk of their disease getting worse will be chosen. These participants must have been on stable treatment for their IgAN for at least three months before the study starts. They will then receive either ravulizumab or a placebo, which is a treatment with no active drug, through an IV infusion based on their weight. The main goal is to see if those who receive ravulizumab have a significant improvement in their condition compared to those who receive the placebo.

    The study will have two main checkpoints. The first one, at Week 34, will check how much protein is in the urine, and the second one, at Week 106, will assess how well the kidneys are filtering waste from the blood. Additionally, a smaller group of participants with more advanced kidney issues will receive ravulizumab to further explore its effects.

    After the study ends at Week 106, participants will have the option to continue receiving ravulizumab in a follow-up period to see how long-term treatment affects their condition. This study is a chance for people with IgAN to potentially slow down their disease progression and improve their quality of life.

    • placebo
    • Ravulizumab
  • Study of belzutifan for treating advanced cancers

    This clinical trial aim is to test out a new drug called belzutifan, also known as MK-6482 or WELIREG™. It’s a pill patient can take once a day, and the main goal is to see if it can shrink or get rid of tumors in folks with certain types of cancer.

    The cancers the researchers are looking at are pheochromocytoma and paraganglioma, which are tumors that start in the adrenal glands or nervous system. Pancreatic neuroendocrine tumors, tumors related to von Hippel-Lindau disease, advanced gastrointestinal stromal tumors, and other solid tumors with certain genetic changes that involve a protein called HIF-2α, there will be also tested.

    The big thing the researchers are  keeping an eye on is the objective response rate, which means how many folks see their tumors shrink or disappear completely while taking this drug. The researchers will be watching closely for any side effects too, of course, to make sure this new medicine is safe.

    • Belzutifan
  • Augmentation of standard chemotherapy with progesterone in adrenocortical cancer

    This is a phase II study aimed at patients with advanced adrenocortical carcinoma (ACC). The main aim of the study is to assess the effectiveness of adding progesterone to a standard chemotherapy regimen. This standard treatment includes a combination of drugs known as etoposide, doxorubicin, cisplatin and mitotane (EDP-M). Scientists believe that adding progesterone in the form of megestrol acetate may improve the effectiveness of the treatment against cancer.

    The test is for patients with advanced or metastatic ACC, which means the cancer has spread beyond its original location. Participants will be divided into two groups. One group will receive a standard treatment of EDP-M plus megestrol acetate, while the other group will receive a treatment of EDP-M plus a placebo. The main aspect researchers will look at is the objective response rate (ORR), which compares how well the cancer responds to treatment in both groups, based on specific criteria known as RECIST.

    • MITOTANE
    • Megestrol Acetate
    • Doxorubicin
    • Cisplatin
    • Etoposide
  • Adjuvant chemotherapy with or without mitotane in the treatment of high-risk postoperative adrenocortical carcinoma

    This trial is focused on patients who have undergone surgery for Adrenocortical Carcinoma (ACC), a rare type of cancer that affects the adrenal glands. The study is particularly interested in those who are at a high risk of the cancer coming back, which is often determined by a measure called Ki67. If Ki67 is 10% or higher, it means there’s a higher chance the cancer could return.

    The main goal of the trial is to compare different treatment approaches after surgery to see which is more effective at preventing the cancer from coming back. One treatment option includes a combination of chemotherapy drugs called Cisplatin and Etoposide, which may or may not be given alongside another drug called Mitotane. Mitotane is commonly used in this setting, but its effectiveness can depend on reaching certain levels in the blood, which can take time. The other option is to either give Mitotane alone or no additional treatment after surgery, depending on what the doctor thinks is best.

    The effectiveness of these treatments will be measured by looking at how long patients remain free from cancer after treatment, a period known as recurrence-free survival (RFS). This will be checked by regular scans of the chest, abdomen, and pelvis.

    • MITOTANE
    • Cisplatin
    • Etoposide
  • To evaluate the effectiveness of cabazitaxel in the treatment of advanced adrenocortical carcinoma after previous treatment

    This trial is focused on exploring the effectiveness of a medication called Cabazitaxel for patients with a rare and aggressive type of cancer known as Adrenocortical Carcinoma (ACC). ACC is challenging to treat, especially in its advanced stages, and the options currently available have limited success. This study is particularly aimed at patients whose cancer has progressed despite undergoing previous chemotherapy treatments.

    Cabazitaxel is a drug that targets cancer cells by interfering with their ability to grow and divide. It is administered through an IV (intravenous) route every three weeks, with a total of up to six cycles of treatment planned. Each cycle of treatment lasts for three weeks, and the start of a new cycle depends on the patient’s recovery from any side effects, particularly focusing on blood cell counts and non-hair loss related side effects.

    An important aspect of this trial is that it does not allow the use of mitotane, a common medication for ACC, unless it is necessary for controlling hormone secretion by the tumor. The study will also look into how cabazitaxel behaves in the body, especially in patients who continue to take mitotane for hormone-related reasons compared to those who do not.

    The main goal of the study is to evaluate the effectiveness of cabazitaxel in improving the condition of patients with ACC after four months of treatment. This will be assessed through CT scans and compared to standard criteria for measuring cancer response to treatment.

    Patients participating in this trial will not be allowed to use certain other medications that could interfere with the study drug or be part of another clinical trial during this study. This study represents a hopeful step towards finding new treatment options for patients with advanced ACC, offering a chance to participate in pioneering research aimed at improving outcomes for this challenging condition.

    • Cabazitaxel
  • Investigating efficacy and safety of new therapy in early-stage Parkinson’s disease

    This clinical trial aims to examine BIIB122, a new medication considered to potentially slow down the progression of early-stage Parkinson’s disease in patients aged between 30–80 years old. Participants will undergo treatment with either BIIB122 or a placebo equal in appearance but devoid of actual medicine. The trial’s routine includes a single daily medication intake for a timeframe between 48 and 144 weeks. To evaluate the medication’s efficacy, patients’ symptoms and their impact on everyday life will be observed using the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS). In addition to this, safety assessment of BIIB122 will be a main focus of the study. The trial treats this as a double-blind study, anonymizing whether a patient takes the BIIB122 drug or a placebo.

    • BIIB122
  • Treatment of lung cancer before and after surgery using various drug combinations

    The NeoCOAST-2 trial is a phase II study evaluating various combinations of anticancer therapies in patients with resectable early-stage non-small cell lung cancer. This study is divided into two stages. The first stage occurs before surgery (neoadjuvant treatment), the next stage after surgery (adjuvant treatment). Researchers will use a drug called Durvalumab, which will be combined with various drugs. The goal is to determine the safety and effectiveness of these regimens for treating early-stage lung cancer, potentially improving treatment outcomes.

    The first group of patients will receive Oleclumab, Durvalumab and a strong drug – Carboplatin/Paclitaxel Pemetrexed/Cisplatin Pemetrexed/Carboplatin. After surgery, they will be given Oleclumab and Durvalumab.

    Patients in the second group will receive Monalizumab, Durvalumab and drugs combined with platinum before surgery. After surgery, they will be given Monalizumab and Durvalumab.

    In the third group, MEDI5752 and drugs combined with platinum are administered before surgery. After surgery, patients will only receive MEDI5752.

    People from group four receive Dato-DXd, Durvalumab, Carboplatin or Cisplatin before surgery. After surgery, they will be given Durvalumab.

    Participants in the fifth group will receive AZD0171, Durvalumab and platinum doublet chemotherapy before surgery. After surgery, patients will receive AZD0171 and Durvalumab.

    • AZD0171- new potential medication for advanced cancer
    • Oleclumab
    • Monalizumab
    • MEDI5752
    • Dato-DXd
    • Pemetrexed
    • Paclitaxel
    • Cisplatin
    • Carboplatin
    • Durvalumab
  • Study on new combination therapy for aggressive lymphoma

    This study is about a less common but severe form of cancer known as Diffuse Large B-Cell Lymphoma (DLBCL). It is testing if a new medication called epcoritamab, given with a mix of other commonly used cancer medicines, can help control the disease better. These other medicines include rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone, which are often collectively referred to as R-CHOP. The study includes about 900 adults from around the world who have recently been diagnosed with this type of lymphoma. They will be split into two groups. One group will get epcoritamab with R-CHOP and then continue with epcoritamab. The other group will get R-CHOP followed by rituximab. Doctors will carefully watch for changes in the disease and for any side effects. There will be many checks on health, including medical exams, blood tests, questionnaires, and monitoring of any side effects.

    • Prednisone
    • Vincristine
    • Doxorubicin
    • Epcoritamab
    • Cyclophosphamide
    • Rituximab
  • Study of the effectiveness of a new drug in the treatment of heart failure and pulmonary hypertension

    This clinical trial explores the potential benefits of AZD3427 for individuals with heart failure (HF) and pulmonary hypertension (PH) Group 2, a condition characterized by increased blood pressure in the lungs due to heart disease. Around 220 participants will be randomly assigned to receive either AZD3427 or a placebo through subcutaneous injections every two weeks for 24 weeks. The trial aims to assess the impact of AZD3427 on reducing pulmonary vascular resistance (PVR) and improving various heart and lung health indicators. Participants will undergo multiple study visits, with the total duration of the study being approximately 32 to 37 weeks.

    • AZD3427- new potential medication for heart failure and pulmonary hypertension
  • Study on sonrotoclax’s effects on returning mantle cell lymphoma

    In this medical trial, doctors are studying the effects of a medication, sonrotoclax (BGB-11417), on people suffering from a type of hard-to-treat blood cancer known as mantle cell lymphoma, which has come back or has not responded to previous treatments. The study is divided into two sections. In the first part, doctors will focus on finding how safe and tolerable this new drug is, the highest dose one can safely take, and the best dose for phase 2 studies. In the second part, they will study how effectively this medicine can treat the cancer at the best dose found in part one. The trial offers hope for better outcomes by exploring this new therapy option, aiming to improve the quality of life for patients facing this challenging condition.

    • BGB-11417/Sonrotoclax
  • Comparing a new treatment with standard care for advanced colorectal cancer

    This research study is for people suffering from a type of bowel cancer that has spread to other parts of the body, known as ‘metastatic colorectal cancer’. The purpose of the study is to compare a new combination of medications against the regular treatments that are already in use. Patients participating in the study will be placed into two groups: one group will receive the standard treatment, and the other group will try a new combination of drugs (tucatinib, trastuzumab, and 5-Fluorouracil, leucovorin,,oxaliplatin). This study will also help to understand the side effects, which are any unexpected symptoms or changes that can occur when taking these medications. Ultimately, the goal of this study is to help learn more about which treatment is more effective in delaying the progression of the disease and improving the patients’ quality of life.

    • levoleucovorin
    • leucovorin
    • Fluorouracil
    • Bevacizumab
    • Cetuximab
    • Tucatinib
    • Oxaliplatin
    • Trastuzumab
  • Testing new medicine for resistant high blood pressure

    In this 20-week trial, the effectiveness, safety, and optimal dosage of a medication known as XXB750 are being evaluated in individuals with resistant high blood pressure (resistant hypertension). This condition persists despite the use of three different blood pressure medications. XXB750 will be administered through subcutaneous injections, and its efficacy will be compared to a placebo. A 2-week preparation period precedes the trial, during which participants receive three doses of the actual trial medicine and one dose as part of the preparation. Following the trial, participants will be monitored for an additional 8 weeks without receiving any trial medicine during this period. The primary focus is on assessing whether XXB750 can effectively reduce blood pressure when measured over a 24-hour period.

    • XXB750
  • Investigating new treatment method for specific head and neck squamous cell carcinoma

    This clinical trial is focused on evaluating the safety and efficacy of a new treatment for patients with a specific type of head and neck cancer caused by Human Papilloma Virus 16 (HPV16) and characterized by the presence of the PD-L1 protein. The treatment involves a combination of a novel drug, BNT113, and a known drug, pembrolizumab. The primary objective is to determine whether this combination is more effective than pembrolizumab alone in assisting the body’s immune system in fighting the cancer. The trial is divided into two parts. In the initial phase, the focus is on assessing the safety of the new drug combination. Subsequently, in the second phase, patients will be randomly assigned to receive either the new combination or pembrolizumab alone. The trial aims to compare the outcomes of the two groups, evaluating tumor response (whether tumors shrink, remain the same, or grow) and monitoring any potential side effects resulting from the treatment.

    • BNT113
    • Pembrolizumab
  • Examining long-term use of osimertinib in treating lung cancer

    This study is investigating a drug known as osimertinib. This includes people who have had successful surgery to remove a type of lung cancer called NSCLC. This cancer is caused by a mutation in a protein called EGFR. The aim of this study is to see if osimertinib can prevent the cancer from coming back within 5 years. The goal is also to ensure the drug’s safety for patients. Patients will receive the drug regardless of whether they received chemotherapy after surgery or not. Here are some of the issues investigators in this study will look at: how long it takes for the cancer to come back, if at all; how many people are alive without the disease after 3, 4 and 5 years; and how long people live after starting the drug. Additionally, a key part of the study is monitoring for any potential side effects.

    • Osimertinib
  • Improving psoriasis treatment for patients: a study on brodalumab

    This detailed study focuses on individuals with moderate-to-severe plaque psoriasis who weigh more than 120 kg. It aims to find out if adjusting the dose of the medication brodalumab can lead to better skin health. In this study, participants receive either an adjusted higher dose of brodalumab or the standard dose. Researchers closely monitor the skin’s response to the treatment, checking if the adjusted dose leads to better skin clearance, meaning fewer or no psoriasis symptoms.

    • Brodalumab

See more clinical trials in other cities in Italy:

.